Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is set to present data on its innovative systemic antitumor virotherapy platform, RTNova (CLD-400), at multiple scientific conferences. These include the International Oncolytic Virotherapy Conference in Rotterdam (Oct. 27-30), the Immuno US 2024 in San Diego (Oct. 28-29), and the Society for Immunotherapy of Cancer Annual Meeting in Houston (November 6-10).
RTNova is designed to address the challenges posed by untargetable and untreatable metastatic diseases by targeting multiple tumor sites and altering the tumor immune microenvironment. This approach not only facilitates easier administration but also broadens the potential patient population who can benefit from this treatment.
“RTNova represents a groundbreaking advancement in cancer therapy, offering a systemic approach that enables us to target and treat metastatic tumors that were previously untouchable,” said Dr. Antonio F. Santidrian, Calidi’s Chief Scientific Officer who has been instrumental in advancing the development of the RTNova platform. “RTNova’s ability to fundamentally change the tumor microenvironment while delivering therapeutic viruses to multiple tumor sites has the potential to unlock new possibilities for patients facing some of the most challenging cancers. Ultimately, we believe RTNova has the potential to transform how we address previously untreatable metastatic diseases.”
To view the full press release, visit: https://ibn.fm/n8hZT
About Calidi Biotherapeutics
Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.
For more information, please visit www.calidibio.com
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
